First human studies with a high-molecular-weight iron chelator (Q47249074)

12 January 2018

title

First human studies with a high-molecular-weight iron chelator (English)

1 reference

12 January 2018

author name string

Dragsten PR

1

1 reference

12 January 2018

Hallaway PE

2

1 reference

12 January 2018

Hanson GJ

3

1 reference

12 January 2018

Berger AE

4

1 reference

12 January 2018

Bernard B

5

1 reference

12 January 2018

Hedlund BE

6

1 reference

12 January 2018

publication date

1 January 2000

1 reference

12 January 2018

published in

Translational Research

1 reference

12 January 2018

volume

135

1 reference

12 January 2018

page(s)

57-65

1 reference

12 January 2018

issue

1

1 reference

12 January 2018

Survival and desferrioxamine in thalassaemia major.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2800%2970021-7

Iron Overload Disorders: Natural History, Pathogenesis, Diagnosis, and Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2800%2970021-7

A risk-benefit assessment of iron-chelation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2800%2970021-7

Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2800%2970021-7

The use of deferoxamine in the management of aluminium accumulation in bone in patients with renal failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2800%2970021-7

Pharmacokinetics of desferrioxamine and of its iron and aluminium chelates in patients on haemodialysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2800%2970021-7

Effect of desferrioxamine on removal of aluminum and iron by coated charcoal haemoperfusion and haemodialysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2800%2970021-7

PREVENTION AND TREATMENT OF ALUMINUM TOXICITY INCLUDING CHELATION THERAPY: STATUS AND RESEARCH NEEDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2800%2970021-7

Aluminum induced anemia: pathogenesis and treatment in patients on chronic hemodialysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2800%2970021-7

Persisting aluminium-related bone disease after cadaveric renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2800%2970021-7

Aluminum chelation: chemistry, clinical, and experimental studies and the search for alternatives to desferrioxamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2800%2970021-7

Attenuation of shock-induced hepatic microcirculatory disturbances by the use of a starch-deferoxamine conjugate for resuscitation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2800%2970021-7

Iron chelation with a deferoxamine conjugate in hemorrhagic shock

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2800%2970021-7

Fluid resuscitation with deferoxamine prevents systemic burn-induced oxidant injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2800%2970021-7

Efficacy and safety of deferoxamine conjugated to hydroxyethyl starch

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2800%2970021-7

Effects of Hydroxyethyl Starch Conjugated Deferoxamine on Myocardial Functional Recovery Following Coronary Occlusion and Reperfusion in Dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2800%2970021-7

Protection against tissue damage in vivo by desferrioxamine: what is its mechanism of action?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2800%2970021-7

Deferoxamine posttreatment reduces ischemic brain injury in neonatal rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2800%2970021-7

Iron-chelating agents in non-iron overload conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2800%2970021-7

Role of iron and oxygen radicals in hemorrhage and shock

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2800%2970021-7

Oxygen free radicals and iron in relation to biology and medicine: some problems and concepts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2800%2970021-7

Protection by desferrioxamine against histopathological changes of the liver in the post-oligaemic phase of clinical haemorrhagic shock in dogs: correlation with improved survival rate and recovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2800%2970021-7

Oxygen-derived free radicals in postischemic tissue injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2800%2970021-7

Deferoxamine (desferrioxamine). New toxicities for an old drug

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2800%2970021-7

Modulation of deferoxamine toxicity and clearance by covalent attachment to biocompatible polymers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2800%2970021-7

Studies in Desferrioxamine and Ferrioxamine Metabolism in Normal and Iron-Loaded Subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2800%2970021-7

Pharmacokinetics and renal elimination of desferrioxamine and ferrioxamine in healthy subjects and patients with haemochromatosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2800%2970021-7

Exchange of iron by gallium in siderophores

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2800%2970021-7

Spectrophotometric study of several sensitive reagents for serum iron

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2800%2970021-7

Hemodynamic Effects of Intraatrial Administration of Deferoxamine or Deferoxamine-Pentafraction Conjugate to Conscious Dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2800%2970021-7

Desferrioxamine-Induced Urinary Iron Excretion in Normal and Iron-Deficient Subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2800%2970021-7

Treatment of rheumatoid arthritis with desferrioxamine: relation between stores of iron before treatment and side effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2800%2970021-7

Neurovascular dysfunction in diabetic rats. Potential contribution of autoxidation and free radicals examined using transition metal chelating agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2800%2970021-7

Diabetes-induced endothelial dysfunction is prevented by long-term treatment with the modified iron chelator, hydroxyethyl starch conjugated-deferoxamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2800%2970021-7

Coronary artery responses to physiological stimuli are improved by deferoxamine but not by L-arginine in non-insulin-dependent diabetic patients with angiographically normal coronary arteries and no other risk factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2800%2970021-7

Treatment of beta-thalassemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-2143%2800%2970021-7

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0022-2143(00)70021-7

1 reference

12 January 2018

PubMed ID

10638695

1 reference

12 January 2018